EFIDAC 24 CHLORPHENIRAMINE MALEATE Drug Patent Profile

Which patents cover Efidac 24 Chlorpheniramine Maleate, and what generic alternatives are available?

Efidac 24 Chlorpheniramine Maleate is a drug marketed by Alza and is included in one NDA.

The generic ingredient in EFIDAC 24 CHLORPHENIRAMINE MALEATE is chlorpheniramine maleate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the chlorpheniramine maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Efidac 24 Chlorpheniramine Maleate

A generic version of EFIDAC 24 CHLORPHENIRAMINE MALEATE was approved as chlorpheniramine maleate by AVANTHI INC on May 13^th, 2009.

Summary for EFIDAC 24 CHLORPHENIRAMINE MALEATE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	81
Patent Applications:	3,641
DailyMed Link:	EFIDAC 24 CHLORPHENIRAMINE MALEATE at DailyMed

US Patents and Regulatory Information for EFIDAC 24 CHLORPHENIRAMINE MALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alza	EFIDAC 24 CHLORPHENIRAMINE MALEATE	chlorpheniramine maleate	TABLET, EXTENDED RELEASE;ORAL	019746-002	Nov 18, 1994		DISCN	No	No

Expired US Patents for EFIDAC 24 CHLORPHENIRAMINE MALEATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alza	EFIDAC 24 CHLORPHENIRAMINE MALEATE	chlorpheniramine maleate	TABLET, EXTENDED RELEASE;ORAL	019746-002	Nov 18, 1994	4,576,604
Alza	EFIDAC 24 CHLORPHENIRAMINE MALEATE	chlorpheniramine maleate	TABLET, EXTENDED RELEASE;ORAL	019746-002	Nov 18, 1994	4,857,330
Alza	EFIDAC 24 CHLORPHENIRAMINE MALEATE	chlorpheniramine maleate	TABLET, EXTENDED RELEASE;ORAL	019746-002	Nov 18, 1994	4,673,405

International Patents for EFIDAC 24 CHLORPHENIRAMINE MALEATE

See the table below for patents covering EFIDAC 24 CHLORPHENIRAMINE MALEATE around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	88884
Germany	3766885
Austria	A72784
United Kingdom	2135880	OSMOTIC DRUG DELIVERY DEVICE
Denmark	162470
Israel	71112	OSMOTIC SYSTEM WITH INSTANT DRUG AVAILABILITY

EFIDAC 24 CHLORPHENIRAMINE MALEATE Market Analysis and Financial Projection Experimental

Chlorpheniramine Maleate Market Dynamics and Financial Trajectory

Market Overview

Chlorpheniramine maleate, an antiallergic medicine, is widely used in the treatment of various allergic conditions, including allergic rhinitis (hay fever), and provides relief from symptoms such as runny nose, sneezing, itchy eyes, and throat irritation. Here’s a detailed look at the market dynamics and financial trajectory of chlorpheniramine maleate.

Market Size and Growth

The global chlorpheniramine maleate market was valued at approximately $468.6 million in 2022 and is projected to reach $751.4 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.9% from 2023 to 2032[1][2][5].

Regional Analysis

• North America: This region accounted for the majority share of the market in 2022 and is expected to remain dominant during the forecast period. The growth is driven by advancements in healthcare infrastructure, easy access to healthcare services, including over-the-counter (OTC) medications for allergic conditions, and an increase in the prevalence of allergic conditions[1][2][5].
• Asia-Pacific: This region is expected to witness the highest growth rate during the forecast period. Factors contributing to this growth include a rise in the prevalence of allergic conditions, an increase in demand for antihistaminic medications, a surge in the geriatric population, and increased air pollution in countries like India, China, Japan, and South Korea[1][4][5].

Market Segmentation

The chlorpheniramine maleate market is segmented by dosage form, application, and distribution channel.

• Dosage Form: The injection segment contributed more than 41% of the revenue share in 2022, indicating a significant preference for injectable forms of the medication[2].
• Application: The allergy segment is expected to expand at a significant CAGR during the forecast period, driven by the increasing prevalence of allergic conditions such as allergic rhinitis and urticaria[2][4].
• Distribution Channel: The market is also segmented by distribution channels, including retail pharmacies, hospitals, and online platforms. Retail pharmacies play a crucial role, especially for OTC medications, catering to consumer demands for convenient and self-directed healthcare solutions[3].

Key Market Drivers

Several factors are driving the growth of the chlorpheniramine maleate market:

• Increasing Prevalence of Allergic Conditions: The rise in allergic diseases such as hay fever, allergic rhinitis, and urticaria is a significant driver. This increase is attributed to factors like urbanization, changing lifestyles, and increased air pollution[1][2][4].
• Advancements in Healthcare: Improvements in healthcare infrastructure and easy access to healthcare services, including OTC medications, are boosting the market[1][5].
• Surge in Geriatric Population: The growing geriatric population is more prone to allergic conditions, thereby increasing the demand for chlorpheniramine maleate[1][4][5].

Market Restraints

Despite the growth, there are several factors that could restrain the market:

• Potential Side Effects: Chlorpheniramine maleate can cause side effects such as drowsiness, dry mouth, blurred vision, and urinary retention, which may deter some consumers[1][4].
• Availability of Alternative Medications: The presence of alternative medications to treat allergies could also hamper the growth of the chlorpheniramine maleate market[1][4].

Competitive Landscape

The market is competitive with several key players:

• Capellon Pharmaceuticals
• GlaxoSmithKline plc
• Viatris Inc.
• Johnson & Johnson
• Sun Pharmaceutical Industries Limited
• Zydus Lifesciences Limited
• Novalab Healthcare Pvt. Ltd.
• Merck & Co., Inc.
• Alkem Laboratories Ltd.
• Bayer AG[1].

Financial Projections

Here are some key financial projections for the chlorpheniramine maleate market:

• Market Size by 2032: Expected to reach $751.4 million[1].
• CAGR: Projected to grow at a CAGR of 4.9% from 2023 to 2032[1][5].
• Regional Growth: Asia-Pacific is expected to grow at the highest CAGR of around 5.5% by 2032[5].

Industry Insights

According to industry experts, the chlorpheniramine maleate market is expected to witness significant growth due to the increasing prevalence of allergic conditions and advancements in healthcare facilities. Here’s an insight from an industry analyst:

"The chlorpheniramine maleate market is expected to witness steady growth in the future. The increase in the prevalence of allergic conditions and rise in awareness among consumers about the symptoms and management of allergies fuel the growth of the market."[1]

Key Takeaways

• The global chlorpheniramine maleate market is projected to grow significantly due to increasing allergic conditions and advancements in healthcare.
• North America dominates the market, but the Asia-Pacific region is expected to grow at the highest rate.
• The market is segmented by dosage form, application, and distribution channel, with the allergy segment and injectable forms being key drivers.
• Potential side effects and the availability of alternative medications are restraints to market growth.

Frequently Asked Questions (FAQs)

Q: What is chlorpheniramine maleate used for? A: Chlorpheniramine maleate is used in the treatment of various allergic conditions such as allergic rhinitis (hay fever), relieving symptoms like runny nose, sneezing, itchy eyes, and throat irritation[1][2][4].

Q: What is the projected market size of chlorpheniramine maleate by 2032? A: The market is expected to reach $751.4 million by 2032[1][5].

Q: Which region is expected to grow at the highest CAGR? A: The Asia-Pacific region is expected to grow at the highest CAGR of around 5.5% by 2032[5].

Q: What are the key drivers of the chlorpheniramine maleate market? A: Key drivers include the increasing prevalence of allergic conditions, advancements in healthcare infrastructure, and a surge in the geriatric population[1][2][4].

Q: What are the potential restraints to the market growth? A: Potential side effects of chlorpheniramine maleate and the availability of alternative medications are significant restraints[1][4].

Cited Sources:

1. Allied Market Research - Chlorpheniramine Maleate Market Statistics and Forecast - 2032
2. GlobeNewswire - Chlorpheniramine Maleate Market is forecasted to Reach USD 744 Million by 2032
3. Cognitive Market Research - Global Chlorpheniramine Maleate Market Report 2024
4. IndustryARC - Chlorpheniramine Maleate Market - Forecast(2024 - 2030)
5. Allied Market Research - Chlorpheniramine Maleate Market | $751.4 Million by 2032